Latest Manufacturing Capacity News

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Chrysos Corporation reported a 25% year-on-year revenue increase in Q3 FY25, driven by strong growth in sample volumes and expanded deployment of its PhotonAssay technology across key mining regions.

HITIQ Ltd has successfully completed a $680,000 placement and launched a $2.92 million rights issue, positioning the company to fund its strategic shift towards the consumer market and expand its footprint in the US.

Merino & Co reported a transformative quarter marked by operational upgrades, new product launches, and the integration of cryptocurrency payments, ending with a robust cash position to fuel future growth.

DroneShield Limited has reported a record-breaking first quarter with $33.5 million in revenue, more than doubling year-over-year, supported by a robust $94.4 million in committed purchase orders and a burgeoning SaaS segment. The company’s expansive $1.6 billion sales pipeline and strong cash position set the stage for accelerated growth in the counter-unmanned systems market.

Lithium Universe Limited’s Definitive Feasibility Study confirms the economic viability of its Bécancour Lithium Refinery, projecting robust returns even amid subdued lithium prices. The project aims to produce 18,270 tonnes per year of battery-grade lithium carbonate, leveraging proven Jiangsu technology and a counter-cyclical development strategy.

Lithium Universe Limited has forged a strategic partnership with Polytechnique Montréal to boost lithium processing expertise and education in Canada, aiming to strengthen the local battery materials supply chain and promote sustainable innovation.

Amaero has completed a A$22 million institutional placement, concluding nearly A$100 million raised since 2022 and positioning itself for commercialisation in FY2026 with a robust balance sheet.

Merino & Co’s successful IPO has injected $6.35 million into the company, enabling a strategic expansion of manufacturing capacity and securing a new facility in Western Australia. The company is now poised to scale globally with automated production and enhanced distribution capabilities.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.